Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

Inclusion Criteria: * Patients between 25 and 75 years old * Patients who have both signs of lower motor neuron(LMN) and upper motor neuron(UMN) degeneration by clinical, electrophysiological or neuropathologic examination * Patients diagnosed as 'Probable' or 'Definite' ALS according to the World Federation of Neurology El Escorial criteria * Patients who have taken Rilutek at stable background dose from 3 months ago at least before screening entry * Patients whose duration of disease is within 5 years from the first diagnosis * Patients with ALSFRS-R score within 31 to 46 at screening * Patients who can visit to a hospital by walk personally or by protector's help * Patients who provide the written consent by oneself or his/her legal representative Exclusion Criteria: * Patients who doesn't appropriate to the diagnostic criteria of ALS * Patients who are diagnosed as primary lateral sclerosis(PLS) or progressive muscular atrophy(PMA) * Patients suspected of adverse effect after stem cell injection(patients suspected of malignant tumor, risk group of psychogenic shock, patients with serious hypertension) * Patients with ALSFRS-R score below 30 at screening * Patients performed ventilator or tracheostomy at screening * Patients performed gastrostomy at screening * Patients unable to assess the efficacy of this clinical trial due to unattainable PFT(Pulmonary Functional Test) or patients with suspected 40% or less of FVC at screening * Patients with finding of myocardial in…